Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis

Next Previous
Trial Profile

A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selinexor (Primary) ; Anagrelide; Androgen receptor modulators; Colony-stimulating factor receptor modulators; Corticosteroid; Fedratinib; Hydroxycarbamide; Interferon; Ruxolitinib
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Therapeutic Use
  • Acronyms XPORT-MF035
  • Sponsors Karyopharm Therapeutics

Most Recent Events

  • 03 Oct 2025 Planned End Date changed from 6 Jan 2025 to 1 Sep 2026.
  • 03 Oct 2025 Planned primary completion date changed from 6 Jan 2025 to 1 Sep 2026.
  • 11 Aug 2025 According to a Karyopharm Therapeutics media release, presented data from the XPORT-MF-035 trial at the European Hematology Association (EHA) 2025 Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top